ClinicalTrials.gg
CompletedNCT03331289Updated Jul 24, 2023Results posted

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

A Phase 4 interventional study of Placebo and Exenatide in Diabetes Mellitus, Type 2, sponsored by The University of Texas Health Science Center at San Antonio. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-24.

Sponsored by The University of Texas Health Science Center at San Antonio · Phase 4, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 127 studies testing exenatide in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Exenatide · Diabetes Mellitus, Type 2.

Enrollment
57th of 127
107 · median 90
Started
2018
the only one that year
Phase 4
46 of 127
none open now
Registered
124th of 127
by date
Lead sponsor
3 of 127
The University of Texas Health Science Center at San Antonio

Among the 127 studies testing exenatide in Diabetes Mellitus, Type 2, this one is the 57th largest by enrollment, is the only one that started in 2018, is one of 46 in phase 4, and was the 124th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 127 studies testing exenatide in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About exenatide

Exenatide: first FDA approval 2005 (BYETTA), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 127 studies testing exenatide in Diabetes Mellitus, Type 2 as a file.
02

Study summary

Research Design/Plan: After screening, each subject will receive 1 measurements of Endogenous Glucose Production [EGP] with prime-continuous Infusion of 3-3H-glucose. After completing the EGP measurement each subject will receive a Double Tracer Oral Glucose Tolerance Test [OGTT].

Methods: Visit 1: Screening. Medical history will be obtained, physical exam performed, and pregnancy test performed.

Visit 2: Endogenous Glucose Production Measurement: The rate of EGP will be measured with 3-3H-glucose.

Visit 3: Double Tracer OGTT

Read the detailed description

Eligible subjects will receive a measurement of endogenous glucose production (EGP) with a prime-continuous infusion of 3-3H-glucose. The EGP measurement will be performed in the morning after a 10-12 hour overnight fast and will last 8 hours (from 6 AM to 2 PM). After a 3-hour tracer equilibration period, subjects (20 per group) will receive one of the following medications: (i) placebo; (ii) exenatide 5 ug subcutaneously; (iii) dapagliflozin (10 mg); and (iv) dapagliflozin 10 mg plus exenatide 5 ug. Following the test medication at 9 AM, blood samples will be drawn every 15 minutes for an additional 5 hours and plasma glucose, insulin, C-peptide, glucagon, cortisol, growth hormone, and catecholamine concentrations and glucose specific activity will be measured.

Visit 1: Screening. Medical history \& physical exam will be performed. Blood will be drawn for fasting plasma glucose [FPG], routine blood chemistries, complete blood count [CBC], lipid profile, HbA1c, and thyroid function [TSH], Urinalysis, electrocardiogram [EKG], albumin/creatinine ratio and pregnancy test will be performed.

Visit 2: EGP Measurement: The rate of endogenous glucose production will be measured with 3-3H-glucose infusion. [3-3H]-glucose infusion will be started at 6 in the morning [AM] and continued until 2:30 afternoon [PM](5 hours after drug administration). At 6 AM a catheter will be placed into an anticubital vein and a prime (40 uCi x FPG/100)- continuous (0.4 uCi) infusion of [3-3H]- glucose will be started and continued until 2:30 PM. (5 hours after drug administration). Participant's hand will be placed in a box heated to 50-60°C (122-140°F). Baseline blood samples will be obtained at-210, -60, -50, -45, -40, -35, -30, -20, -10, and 0 . After 3.5 hours of tracer equilibration blood samples will be obtained every 10-20 minutes from 9 AM to 2 PM. Plasma glucose, insulin, C-peptide, glucagon, cortisol, growth hormone, and catecholamine concentrations, and [3-3H]-glucose specific activity will be measured. Urine will be collected from 6 to 9 AM and from 9 AM to 2 PM. Urinary volume and glucose concentration will be measured and urinary glucose excretion rate calculated. The study will end at 2:30 PM.

Visit 3: Double Tracer Oral Glucose Tolerance Test [OGTT]: Within the week after the measurement of EGP, all subjects will have a 5-hour OGTT with measurement of plasma glucose, insulin (I), C-peptide (CP), and glucagon concentrations at -180, -6-, -5-, -45, -40, -35, -30, -20, -10, 0 and every 15-30 minutes thereafter to obtain a measure of overall glucose tolerance, insulin secretion (CP0-120/G0-120), insulin sensitivity ([Matsuda Index=MI]), beta cell function, (CP0-120/G0-120 x MI), and suppression of plasma glucagon concentration (64). At 7 AM a catheter will be placed into an antecubital vein and a prime (25 uCi x FPG/100)- continuous (0.25 uCi) infusion of [3-3H]- glucose will be started and continued until 3 PM. Urinary volume and glucose concentration will be measured and urinary glucose excretion rate calculated.

HbA1c will be measured 2x, 1 on the day of the OGTT \& 1 on the day of the EGP measurement.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Health Status: Type 2 Diabetes Mellitus according to ADA criteria (subjects must be in good general health as determined by physical exam, medical history, blood chemistry-CBC, TSH, T4, and urinalysis)
  • : 21-45kg/m
  • >7.0% and \<10.5%
  • Medication: Drug naïve and/or on a stable dose of metformin and/or sulfonylurea (more than 3 months)

Exclusion criteria

Exclusion Criteria:

  • Health Status: Type 1 Diabetics
  • Proliferative diabetic retinopathy
  • Plasma Creatinine greater than 1.4mg/dL in females or greater than 1.5mg/dL in males, or 24 hour urine albumin excretion greater than 300mg/dL
  • Medication: Subjects taking drugs known to affect glucose metabolism (other than metformin and sulfonylurea)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.

    Drug: Placebo

  • Active comparator
    Exenatide

    we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.

    Drug: Exenatide

  • Active comparator
    Dapagliflozin

    we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.

    Drug: Dapagliflozin

  • Active comparator
    Exenatide and Dapagliflozin

    we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.

    Drug: Exenatide and Dapagliflozin

Interventions

  • DrugPlacebo

    Placebo will be administered to 20 subjects after a 3 hour tracer equilibration period

    Also known as: Placebo drug

  • Exenatide will be administered to 20 subjects after a 3 hour tracer equilibration period

    Also known as: Byetta, Bydureon

  • Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period

    Also known as: Farxiga

  • DrugExenatide and Dapagliflozin

    Drug pages: ExenatideStudies of ExenatideExenatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DapagliflozinStudies of DapagliflozinDapagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Exenatide and Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period

    Also known as: Byetta plus Dapagliflozin

06

What researchers measure

Primary outcomes

  1. Change in EGP From Baseline to Post-oral Glucose Load.

    The difference in rate of EGP during the last hour of the study (from 240-300 minutes) between drug-treatment and placebo treatment studies represents the effect of drug treatment on EGP, which will be compared among the 3 acute drug treatments (exenatide; dapagliflozin; exenatide plus dapagliflozin this data includes change in EGP above baseline following dapagliflozin alone vs dapagliflozin/exenatide) with ANOVA.

    Time frame: From baseline [-35 to 0min] to the last hour post-glucose load [240-300 minutes]

07

Results

Posted Jul 24, 2023

Participant flow

Participant flow — Overall Study
MilestoneType 2 Diabetes on DapagliflozinType 2 Diabetes on Oral PlaceboType 2 Diabetes on ExenatideType 2 Diabetes on Exenatide Plus Dapagliflozin
Started30232826
Completed25152525
Not completed5831

Outcome measures

PrimaryChange in EGP From Baseline to Post-oral Glucose Load.

The difference in rate of EGP during the last hour of the study (from 240-300 minutes) between drug-treatment and placebo treatment studies represents the effect of drug treatment on EGP, which will be compared among the 3 acute drug treatments (exenatide; dapagliflozin; exenatide plus dapagliflozin this data includes change in EGP above baseline following dapagliflozin alone vs dapagliflozin/exenatide) with ANOVA.

Time frame:
From baseline [-35 to 0min] to the last hour post-glucose load [240-300 minutes]
Reported as:
Mean · mg/kg.min
Change in EGP From Baseline to Post-oral Glucose Load.
mg/kg.minPlaceboExenatideDapagliflozinExenatide and Dapagliflozin
Change in EGP From Baseline to Post-oral Glucose Load.-0.03 ± 0.02-0.18 ± 0.020.14 ± 0.03-0.08 ± 0.03

Adverse events

Collected over 4 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/15 (0%)0/15 (0%)0/15 (0%)
Exenatide0/25 (0%)0/25 (0%)4/25 (16%)
Dapagliflozin0/25 (0%)0/25 (0%)7/25 (28%)
Exenatide and Dapagliflozin0/25 (0%)0/25 (0%)6/25 (24%)
Most frequent other events
Most frequent other events
EventPlaceboExenatideDapagliflozinExenatide and Dapagliflozin
Genital MycosisInfections and infestations0/150/257/254/25
Nausea and VomitingGastrointestinal disorders0/154/250/252/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboExenatideDapagliflozinExenatide and DapagliflozinTotal
Mean54 ± 352 ± 351 ± 249 ± 251 ± 3
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboExenatideDapagliflozinExenatide and DapagliflozinTotal
Female1017151658
Male5810932
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboExenatideDapagliflozinExenatide and DapagliflozinTotal
Hispanic or Latino1115141656
Not Hispanic or Latino21011932
Unknown or Not Reported20002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboExenatideDapagliflozinExenatide and DapagliflozinTotal
American Indian or Alaska Native20002
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American479828
White918161760
More than one race00000
Unknown or Not Reported00000
ENDOGENOUS GLUCOSE PRODUCTION [EGP]
ENDOGENOUS GLUCOSE PRODUCTION [EGP](mg/kg.min)PlaceboExenatideDapagliflozinExenatide and DapagliflozinTotal
Mean2.30 ± 0.052.33 ± 0.132.27 ± 0.042.41 ± 0.102.33 ± 0.25
08

Study locations

1 site
  • University Health System Texas Diabetic Institute
    San Antonio, Texas 78207, United States
09

References and documents

Publications

  • Alatrach M, Agyin C, Solis-Herrera C, Lavryneko O, Adams J, Gastaldelli A, Triplitt C, DeFronzo RA, Cersosimo E. Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose. Diabetes Care. 2022 Jun 2;45(6):1372-1380. doi: 10.2337/dc21-1798. PubMed 35235659 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All collected IPD, all IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be shared once study closes to enrollment and all data are analyzed and published. Informed consent documentation will be available for sharing.....

Access criteria: Access will be available through the journal website and on request through the PI.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Mar 2022, 49 months.

Results were first posted in Jul 2023, 1 year 3 months after primary completion.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's 49 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2017
First posted
Nov 6, 2017
StartActual
Feb 28, 2018
Primary completionActual
Mar 31, 2022
CompletionActual
Nov 4, 2022
Results first posted
Jul 24, 2023
Last update
Jul 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03331289
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Feb 28, 2018
Primary completion
Mar 31, 2022
Completion
Nov 4, 2022
Results posted
Jul 24, 2023
Last update
Jul 24, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Exenatide · Dapagliflozin

Start the discussion